United Therapeutics (UTHR) Enterprise Value (2009 - 2026)

United Therapeutics has disclosed Enterprise Value across 18 years of filings, most recently posting -$2.2 billion for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$2.2 billion, up 35.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.2 billion (up 35.15% YoY), and the FY2025 annual result was -$2.9 billion, up 10.61% from the prior year.
• Enterprise Value came in at -$2.2 billion for Q1 2026 at United Therapeutics, up from -$2.9 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$2.2 billion in Q1 2026 to a low of -$3.3 billion in Q3 2024.
• The 5-year median for Enterprise Value is -$2.9 billion (2023), against an average of -$2.8 billion.
• Across the five-year window, Enterprise Value sank 47.03% in 2022 and jumped 35.15% in 2026, its largest moves.
• United Therapeutics' Enterprise Value stood at -$2.8 billion in 2022, then dropped by 5.47% to -$3.0 billion in 2023, then declined by 9.11% to -$3.3 billion in 2024, then gained by 10.61% to -$2.9 billion in 2025, then grew by 26.25% to -$2.2 billion in 2026.
• The last three Enterprise Value figures came in at -$2.2 billion (Q1 2026), -$2.9 billion (Q4 2025), and -$2.8 billion (Q3 2025), per Business Quant data.